Literature DB >> 9673363

The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer.

R Sanguedolce1, G Vultaggio, F Sanguedolce, G Modica, F Li Volsi, G Diana, G Guereio, L Bellanca, L Rausa.   

Abstract

Inhibition of Thymidylate Synthase (TS) by the 5-Fluorouracil (5Fu) active metabolite Fluoro-deoxy-uridine-monophosphate (FdUMP) is considered to be the main mechanism of action of 5Fu. TS level from tumors and normal mucosa of 62 untreated patients who underwent surgery for primary colorectal adenocarcinoma was performed. The aim of this study was to evaluate the possibility of considering the TS level as a prognostic factor of the disease. A large variation in the level of the enzyme was found among tumors. Our data demonstrate that there is no association with age, sex, and tumor size; however there are significant relationships between TS levels and staging and histological grading. In fact the TS values are higher in Dukes' A and in G1 than in Dukes' D and G3 tumors (p < 0.05). Another significant association has been found between the TS level and tumor site: pts with right colon neoplasias had higher TS levels than pts with left and rectum ones. An interesting trend was found between the TS levels and survival parameters. Pts who had lower TS levels had a significantly increased risk of death (p < 0.05) over pts with a higher outcome. Our data support the hypothesis that a high TS level is a favourable prognostic factor in human untreated colorectal carcinomas according to our previous preliminary data (1).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673363

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Authors:  Silke Lassmann; Michael Hennig; Robert Rosenberg; Jörg Nährig; Joachim Schreglmann; Friedemann Krause; Manuela Poignee-Heger; Hjalmar Nekarda; Heinz Höfler; Martin Werner
Journal:  Int J Colorectal Dis       Date:  2005-08-13       Impact factor: 2.571

2.  Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.

Authors:  Kwang Wook Suh; Joo Hyung Kim; Young Bae Kim; Jeongmi Kim; Soohyun Jeong
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

3.  Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Ewa Majdanik; Maria Chosia; Dariusz Bielicki; Jozef Kladny; Mariusz Kaczmarczyk; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2009-05-15       Impact factor: 4.064

4.  Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.

Authors:  Manish Patel; Ram Agarwal; Bach Ardalan
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

Review 5.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

6.  Prognostic and predictive value of thymidylate synthase expression in colon cancer.

Authors:  Gerasimos Tsourouflis; Stamatios E Theocharis; Anastasia Sampani; Athina Giagini; Alkiviadis Kostakis; Gregory Kouraklis
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

7.  Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.

Authors:  J P Burke; J H M Prehn; E O'Connell; I S Reynolds; M Salvucci; D A McNamara
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

8.  Molecular predictors of lymph node metastasis in colon cancer: increased risk with decreased thymidylate synthase expression.

Authors:  Avo Artinyan; Rahila Essani; Jeffrey Lake; Andreas M Kaiser; Peter Vukasin; Peter Danenberg; Kathleen Danenberg; Robert Haile; Robert W Beart
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

9.  Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.

Authors:  N A Wong; L Brett; M Stewart; A Leitch; D B Longley; M G Dunlop; P G Johnston; A M Lessells; D I Jodrell
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

10.  Role of biological markers in the clinical outcome of colon cancer.

Authors:  O Nanni; A Volpi; G L Frassineti; F De Paola; A M Granato; A Dubini; W Zoli; E Scarpi; D Turci; G Oliverio; A Gambi; D Amadori
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.